EGFR and lung carcinoma: Furthermore, the intermittent drug treatment was less effectively induced the emergence of the EGFR T790M mutation which is the most common resistance mechanism found in EGFR-mutant lung cancer patients treated by EGFR-TKI, compared with the continuous drug treatment.